Skip to main content
SpringerLink
Log in

Gender aspects in haematology and oncology: Overview and own observations in lung cancer

  • Leading article
  • Published:
memo - Magazine of European Medical Oncology Aims and scope Submit manuscript

Summary

In this article, different aspects of gender (used here both in the sense of sex, reflecting somatic differences between men and women, and gender, reflecting psychosocial differences) are reviewed. In preclinical research, are there gender aspects taken into consideration, e.g. in cell culture assays or animal models? What about gender aspects in cancer prevention, epidemiology and tumourigenesis, including gender-related susceptibilities towards environmental carcinogens? To offer some results from our own research in this field, original data on gender-related differences of symptoms and comorbidities in lung cancer at initial diagnosis are presented. Of importance, but still widely neglected in the haemato-oncologic literature is the influence of gender on the accessibility to diagnostic procedures and treatment. Gender-specific pharmacodynamic peculiarities and differences in treatment outcome and prognosis of various tumour entities are presented. Since gender aspects are often not put in focus of cancer research, relevant literature on this topic is rather sparse and difficult to search. In this regard, the authors make no claim to provide a comprehensive review.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

References

  • WHO statistics 2008, http://apps.who.int/globalatlas/interactiveMapping/MainFrame2.asp

  • Hammoud Z, Tan B, Badve S, Bigsby RM. Estrogen promotes tumor progression in a genetically defined mouse model of lung adenocarcinoma. Endocr Relat Cancer, 15: 475–483, 2008

    Article  PubMed  CAS  Google Scholar 

  • Malkinson AM. The genetic basis of susceptibility to lung tumor in mice, Toxicology, 54: 241–71, 1989

    Article  PubMed  CAS  Google Scholar 

  • Zheng S, El-Naggar AK, Kim ES, Kurie JM, Lozano G. A genetic mouse model for metastatic lung cancer with gender differences in survival. Oncogene, 26: 6896–6904, 2007

    Article  PubMed  CAS  Google Scholar 

  • Belinsky SA, Klinge DM, Stidley CA, et al. Inhibition of DNA methylation and histone deacetylation prevents murine lung cancer. Cancer Res, 63: 7089–7093, 2003

    PubMed  CAS  Google Scholar 

  • Wang AG, Moon HB, Lee MR, et al. Gender-dependent hepatic alterations in H-ras12V transgenic mice. J Hepatol, 43: 836–844, 2005

    Article  PubMed  CAS  Google Scholar 

  • Naugler WE, Sakurai T, Kim S, et al. Gender disparity in liver cancer due to sex differences in MyD88-dependent IL-6 production. Science, 317: 121–124, 2007

    Article  PubMed  CAS  Google Scholar 

  • Leenders MW, Nijkamp MW, Borel Rinkes IH. Mouse models in liver cancer research: a review of current literature. World J Gastroenterol, 14: 6915–6923, 2008

    Article  PubMed  CAS  Google Scholar 

  • Ma WL, Hsu C, Wu MH, et al. Androgen receptor is a new potential therapeutic target for the treatment of hepatocellular carcinoma, Gastroenterology, 135: 947–955, 2008

    Article  PubMed  CAS  Google Scholar 

  • Nakau M, Miyoshi H, Seldin MF, Imamura M, Oshima M, Taketo MM. Hepatocellular carcinoma caused by loss of heterozygosity in Lkb1 gene knockout mice. Cancer Res, 62: 4549–4553, 2002

    PubMed  CAS  Google Scholar 

  • Lakhtakia R, Kumar V, Reddi H, Mathur M, Dattagupta S, Panda SK. Hepatocellular carcinoma in a hepatitis B 'x' transgenic mouse model: A sequential pathological evaluation. J Gastroenterol Hepatol, 18: 80–91, 2003

    Article  PubMed  Google Scholar 

  • Moriya K, Fujie H, Shintani Y, et al. The core protein of hepatitis C virus induces hepatocellular carcinoma in transgenic mice. Nat Med, 4: 1065–1067, 1998

    Article  PubMed  CAS  Google Scholar 

  • Krebs in Deutschland 2005/2006. Häufigkeiten und Trends. 7. Ausgabe. Robert Koch-Institut (Hrsg) und die Gesellschaft der epidemiologischen Krebsregister in Deutschland e. V. (Hrsg). Berlin, 2010; ISBN978-3-89606-207-9

  • Oberaigner W, Mühlböck H, Harrasser L. Tumorregister Tirol, Bericht des Diagnosejahres 2007. IET – Institut für klinische Epidemiologie der TILAK GmbH. Innsbruck, Oktober 2009. www.iet.at

  • La Vecchia C, Bosetti C, Lucchini F, et al. Cancer mortality in Europe, 2000–2004, and an overview of trends since 1975. Ann Oncol, 21: 1323–1360, 2010

    Article  PubMed  CAS  Google Scholar 

  • Kirsch-Volders M, Bonassi S, Herceg Z, Hirvonen A, Möller L, Phillips DH. Gender-related differences in response to mutagens and carcinogens. Mutagenesis, 25: 213–221, 2010

    Article  PubMed  CAS  Google Scholar 

  • Petrelli NJ, Winer EP, Brahmer J, et al. Clinical Cancer Advances 2009: major research advances in cancer treatment, prevention, and screening--a report from the American Society of Clinical Oncology. Clin Oncol, 27: 6052–6069, 2009

    Article  Google Scholar 

  • Egleston BL, Meireles SI, Flieder DB, Clapper ML. Population-based trends in lung cancer incidence in women. Semin Oncol, 36: 506–515, 2009

    Article  PubMed  Google Scholar 

  • Fleitmann S, Dohnke B, Balke K, Rustler C, Sonntag U. Women and smoking. A challenge for the tobacco control policy in Germany. Bundesgesundheitsblatt Gesundheitsforschung Gesundheitsschutz, 53: 117–124, 2010

    Article  PubMed  CAS  Google Scholar 

  • Subramanian J, Govindan R. Molecular genetics of lung cancer in people who have never smoked. Lancet Oncol, 9: 676–682, 2008

    Article  PubMed  CAS  Google Scholar 

  • Wang XR, Chiu YL, Qiu H, Au JS, Yu IT. The roles of smoking and cooking emissions in lung cancer risk among Chinese women in Hong Kong. Ann Oncol, 20: 746–751, 2009

    Article  PubMed  Google Scholar 

  • Novello S, Baldini E. Women and lung cancer. Ann Oncol, (Suppl. 2): ii79–82, 2006

    Article  Google Scholar 

  • Dally H, Edler L, Jäger B, Schmezer P, et al. The CYP3A4*1B allele increases risk for small cell lung cancer: effect of gender and smoking dose. Pharmacogenetics, 13: 607–618, 2003

    Article  PubMed  CAS  Google Scholar 

  • Tanaka T, Matsuoka M, Sutani A, et al. Frequency of and variables associated with the EGFR mutation and its subtypes. Int J Cancer, 126: 651–655, 2010

    Article  PubMed  CAS  Google Scholar 

  • Radzikowska E, Głaz P, Roszkowski K. Lung cancer in women: age, smoking, histology, performance status, stage, initial treatment and survival. Population-based study of 20 561 cases. Ann Oncol, 13: 1087–1093, 2002

    Article  PubMed  CAS  Google Scholar 

  • Shafer D, Albain K. Lung cancer outcomes in women. Semin Oncol, 36: 532–541, 2009

    Article  PubMed  CAS  Google Scholar 

  • Fu JB, Kau TY, Severson RK, Kalemkerian GP. Lung cancer in women: analysis of the national Surveillance, Epidemiology, and End Results database. Chest, 127: 768–777, 2005

    Article  PubMed  Google Scholar 

  • Sterlacci W, Tzankov A, Veits L, et al. The prognostic impact of sex on surgically resected non-small cell lung cancer depends on clinicopathologic characteristics. Am J Clin Pathol, 135: 611–618, 2011

    Article  PubMed  Google Scholar 

  • Li YJ, Tsai YC, Chen YC, Christiani DC. Human papilloma virus and female lung adenocarcinoma. Semin Oncol, 36: 542–552, 2009

    Article  PubMed  Google Scholar 

  • Giuliano AR, Lee JH, Fulp W, et al. Incidence and clearance of genital human papillomavirus infection in men (HIM): a cohort study. Lancet, 377: 932–940, 2011

    Article  PubMed  Google Scholar 

  • Giuliano AR, Tortolero-Luna G, Ferrer E, et al. Epidemiology of human papillomavirus infection in men, cancers other than cervical and benign conditions. Vaccine, 26 (Suppl. 10) 10:K17–28, 2008

    Article  PubMed  Google Scholar 

  • Morton LM, Wang SS, Devesa SS, Hartge P, Weisenburger DD, Linet MS. Lymphoma incidence patterns by WHO subtype in the United States, 1992–2001. Blood, 107: 265–276, 2006

    Article  PubMed  CAS  Google Scholar 

  • Mitterlechner T, Fiegl M, Mühlböck H, Oberaigner W, Dirnhofer S, Tzankov A. Epidemiology of non-Hodgkin lymphomas in Tyrol/Austria from 1991 to 2000. Clin Pathol, 59: 48–55, 2006

    Article  CAS  Google Scholar 

  • Doubek M, Mayer J, Obrtlíková P, et al. Modern and conventional prognostic markers of chronic lymphocytic leukemia (CLL) in the everyday hematological practice. Eur J Haematol, doi: 10.1111/j.1600-0609.2011.01639.x. [Epub ahead of print], 2006

  • Fiegl M, Hilbe W, Auberger J, et al. Twelve-year retrospective analysis of lung cancer–The TYROL Study: Daily routine in 1,424 patients (1995–2006). J Clin Oncol, 26 (15S): 19063, 2008

    Google Scholar 

  • Pircher A, Ulsperger E, Hack R, et al. Basic clinical parameters predict gefitinib efficacy in non-small cell lung cancer. Anticancer Res, in press, 2011

  • Miaskowski C. Gender differences in pain, fatigue, and depression in patients with cancer. J Natl Cancer Inst Monogr, 32: 139–143, 2004

    Article  PubMed  Google Scholar 

  • Walsh D, Donnelly S, Rybicki L. The symptoms of advanced cancer: relationship to age, gender, and performance status in 1,000 patients. Support Care Cancer, 8: 175–179, 2000

    Article  PubMed  CAS  Google Scholar 

  • Wardle J, Miles A, Atkin W. Gender differences in utilization of colorectal cancer screening. J Med Screen, 12: 20–27, 2005

    Article  PubMed  CAS  Google Scholar 

  • Meissner HI, Breen N, Klabunde CN, Vernon SW. Patterns of colorectal cancer screening uptake among men and women in the United States. Cancer Epidemiol Biomarkers Prev, 15: 389–394, 2006

    Article  PubMed  Google Scholar 

  • Sieverding M, Matterne U, Ciccarello L. Gender differences in FOBT use: evidence from a large German survey. Z Gastroenterol, 46 (Suppl. 1) 1: S47–S51, 2008

    Article  PubMed  Google Scholar 

  • Shugarman LR, Mack K, Sorbero ME, et al. Race and sex differences in the receipt of timely and appropriate lung cancer treatment. Med Care, 47: 774–781, 2009

    Article  PubMed  Google Scholar 

  • Potosky AL, Saxman S, Wallace RB, Lynch CF. Population variations in the initial treatment of non-small-cell lung cancer. J Clin Oncol, 22: 3261–3268, 2004

    Article  PubMed  Google Scholar 

  • Dulabon LM, Lowrance WT, Russo P, Huang WC. Trends in renal tumor surgery delivery within the United States. Cancer, 116: 2316–2321, 2010

    PubMed  Google Scholar 

  • Paulson EC, Wirtalla C, Armstrong K, Mahmoud NN. Gender influences treatment and survival in colorectal cancer surgery. Dis Colon Rectum, 52: 1982–1991, 2009

    Article  PubMed  Google Scholar 

  • Martling A, Granath F, Cedermark B, Johansson R, Holm T. Gender differences in the treatment of rectal cancer: a population based study. Eur J Surg Oncol, 35: 427–433, 2009

    Article  PubMed  CAS  Google Scholar 

  • Kloft C, Wallin J, Henningsson A, Chatelut E, Karlsson MO. Population pharmacokinetic-pharmacodynamic model for neutropenia with patient subgroup identification: comparison across anticancer drugs. Clin Cancer Res, 12: 5481–5490, 2006

    Article  PubMed  CAS  Google Scholar 

  • Stein BN, Petrelli NJ, Douglass HO, Driscoll DL, Arcangeli G, Meropol NJ. Age and sex are independent predictors of 5-fluorouracil toxicity. Analysis of a large scale phase III trial. Cancer, 75: 11–17, 1995

    Article  PubMed  CAS  Google Scholar 

  • Lyman GH, Dale DC, Friedberg J, Crawford J, Fisher RI. Incidence and predictors of low chemotherapy dose-intensity in aggressive non-Hodgkin's lymphoma: a nationwide study. J Clin Oncol, 22: 4302–4311, 2004

    Article  PubMed  CAS  Google Scholar 

  • Aapro MS, Bohlius J, Cameron DA, et al. European Organisation for Research and Treatment of Cancer. 2010 update of EORTC guidelines for the use of granulocyte-colony stimulating factor to reduce the incidence of chemotherapy-induced febrile neutropenia in adult patients with lymphoproliferative disorders and solid tumours. Eur J Cancer, 47: 8–32, 2011

    Article  PubMed  CAS  Google Scholar 

  • Dooley MJ, Poole SG, Rischin D, Webster LK. Carboplatin dosing: gender bias and inaccurate estimates of glomerular filtration rate. Eur J Cancer, 38: 44–51, 2002

    Article  PubMed  CAS  Google Scholar 

  • Calvert AH, Egorin MJ. Carboplatin dosing formulae: gender bias and the use of creatinine-based methodologies. Eur J Cancer, 38: 11–16, 2002

    Article  PubMed  CAS  Google Scholar 

  • Micheli A, Ciampichini R, Oberaigner W, et al. The advantage of women in cancer survival: an analysis of EUROCARE-4 data. EUROCARE Working Group. Eur J Cancer, 45: 1017–1027, 2009

    Article  PubMed  CAS  Google Scholar 

  • Shigematsu H, Lin L, Takahashi T, et al. Clinical and biological features associated with epidermal growth factor receptor gene mutations in lung cancers. J Natl Cancer Inst, 97: 339–346, 2005

    Article  PubMed  CAS  Google Scholar 

  • Ramchandran K, Patel JD. Sex differences in susceptibility to carcinogens. Semin Oncol, 36: 516–523, 2009

    Article  PubMed  CAS  Google Scholar 

  • Miller VA, Kris MG, Shah N, et al. Bronchioloalveolar pathologic subtype and smoking history predict sensitivity to gefitinib in advanced non-small-cell lung cancer. J Clin Oncol, 22: 1103–1109, 2004

    Article  PubMed  CAS  Google Scholar 

  • Shah NT, Kris MG, Pao W, et al. Practical management of patients with non-small-cell lung cancer treated with gefitinib. J Clin Oncol, 23: 165–174, 2005

    Article  PubMed  CAS  Google Scholar 

  • Mok TS, Wu YL, Thongprasert S, et al. Gefitinib or carboplatin-paclitaxel in pulmonary adenocarcinoma. N Engl J Med, 361: 947–957, 2009

    Article  PubMed  CAS  Google Scholar 

  • Shepherd FA, Rodrigues Pereira J, Ciuleanu T, et al. National Cancer Institute of Canada Clinical Trials Group. Erlotinib in previously treated non-small-cell lung cancer. N Engl J Med, 353: 123–132, 2005

    Article  PubMed  CAS  Google Scholar 

  • Sandler A, Gray R, Perry MC, et al. Paclitaxel-carboplatin alone or with bevacizumab for non-small-cell lung cancer. N Engl J Med, 355: 2542–2550, 2006

    Article  PubMed  CAS  Google Scholar 

  • Reck M, von Pawel J, Zatloukal P, et al. Phase III trial of cisplatin plus gemcitabine with either placebo or bevacizumab as first-line therapy for nonsquamous non-small-cell lung cancer: AVAil. J Clin Oncol, 27: 1227–1234, 2009

    Article  PubMed  CAS  Google Scholar 

  • Pirker R, Pereira JR, Szczesna A, et al. FLEX Study Team. Cetuximab plus chemotherapy in patients with advanced non-small-cell lung cancer (FLEX): an open-label randomised phase III trial. Lancet, 373: 1525–1531, 2009

    Article  PubMed  CAS  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Department of Internal Medicine V, Hemato-Oncology, Innsbruck Medical University, Anichstrasse 35, 6020, Innsbruck, Austria

    M. Fiegl

  2. Section for Cellular Biology, Biocentre, Innsbruck Medical University, Innsbruck, Austria

    C. Thöni

  3. Womens Health Centre of Innsbruck Medical University Hospital, Innsbruck Medical University, Innsbruck, Austria

    M. Hochleitner

Authors
  1. M. Fiegl
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. C. Thöni
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. M. Hochleitner
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to M. Fiegl.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Fiegl, M., Thöni, C. & Hochleitner, M. Gender aspects in haematology and oncology: Overview and own observations in lung cancer. memo 4, 209–216 (2011). https://doi.org/10.1007/s12254-011-0305-0

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s12254-011-0305-0

Keywords

Search

Navigation